TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Relative single dose bioavailability (AUC48)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum HBsAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum HBV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Upper gastrointestinal transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Metabolomics of serum and gut microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proteomic profiling of serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2 post-prandial gas exchange
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VCO2 post-prandial gas exchange
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EE post-prandial gas exchange
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction of lower anterior crowding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wearable sensor device compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Accuracy of functional evaluation using the Duchenne Video Assessment (DVA) tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for use of the wearable sensor device and DVA tool
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain intensity VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity PSFP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK exposure parameters of digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CLAD-V performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake value of 99mTc-CNDG in malignant tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesions detected by 99mTc-CNDG SPECT/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Oral glucose tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fetal macrosomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical and virological cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical recovery defined by the absence of clinical signs of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Center for epidemiological studies - depression (CES-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean decrement in plaque score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean increment in gingival health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the incidence of all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Median time to reach deficit of 100 cc
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective status on GOG performance scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Days of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysmenorrhea Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Working Ability
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: COVID-19 confirmation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety as measured by Clavien-Dindo grading system
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in small bowel SUV/SUVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dietary intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of minor phytocannabinoids and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine concentration of minor phytocannabinoids and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite complication
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of Genetic DAO Deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Malaria incidence per person
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of radiation caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Xe-MRI Apparent Diffusion Coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Completing 9 Weeks
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cortico-cortical evoked potential (ccEP) latencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in cortico-cortical evoked potential (ccEP) amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in pain intensity and frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Fruit and Vegetable Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Changes in Skin Carotenoid Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Times Being Physically Active
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in hourly cough frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Cytopenias
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment related adverse event rates
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate (Phase II) RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response rate (Phase II) Immune-Modified RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Gamma camera-based whole-body [99mTc]Tc(CO)3-(HE)3-Ec1 uptake value (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPECT-based [99mTc]Tc(CO)3-(HE)3-Ec1 value in tumor lesions (counts)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in patient reported Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in DNA Methylation patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Oxygen Therapy Initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Oxygen Therapy Use Within the First 12 Months of Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: healthy live birth
Endpoint domain: Mortality/survival
Primary endpoint: Blood iron status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recurrent RRD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neutrophil gelatinase associated lipocalin (NGAL) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of ENX-101 in reducing focal seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to serum creatinine value of less than 1.5 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Lumbar CSF protein marker levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Evolution of WHO-5
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in Intimate partner violence perpetration
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Intimate partner violence victimization
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Alcohol Use
Endpoint domain: Adverse events/effects
Primary endpoint: Detection rate of alterations of anti-epidermal growth factor receptor primary resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of Sinusoidal obstruction syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Idiopathic or Non-Infective Pulmonary Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Mucositis ≥ Grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Delayed Engraftment of Neutrophils
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Failed Engraftment of Neutrophils
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Delayed Engraftment of Platelets
Endpoint domain: Adverse events/effects
Primary endpoint: First intervention free survival (FIFS) at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Change in Episodic Memory Task Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in neurovascular reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in structural connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG-power in alpha band
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Basal numeration of circulating ITC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Basal expression level of Ki67 among circulating ITC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IFN-ɣ, IL-4 and IL-17 production of iNKT, MAIT, γδ-T and innate CD8(+) T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of students who chose cola
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Long-term Implant Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bedtime and getting up time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs of tiredness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of interactions during meals
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Maximum tolerated dose of abemaciclib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to intervention - number of completed sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: presence of adverse or undesirable effects during the intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability: Overall experience
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Shoulder Joint Range of Motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skeletal muscle index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with decision making process
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction with proactive care planning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Well child visits attended per month
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent Change in Cerebral Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postural Symmetry Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biopsy Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Timed Up and Go Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 10 meter walk test self-selected pace
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain level: pain intensity via Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain level: pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of anastomosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: variation in 12-item neurotoxicity questionnaire (Ntx-12) total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: variation in pain rating scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: the percentage of patients with peripheral sensory neuropathy grade ≥ 2
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Hand strength - Manual Motor Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hand strength - Dynamometer grip and pinch strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hand function (Velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type of cell death
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time registrations of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Patient registration of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Discriminative capacity of hepcidin to differentiate response to iron therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ballistocardiography waveform
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anti-PT IgG and IgA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Signs of microstructural myelopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Signs of metabolic myelopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Remote spinal cord atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnosis of placenta accreta spectrum disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathological diagnosis of placenta accreta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inspiratory muscle training compliance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: rilzabrutinib Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rilzabrutinib AUClast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rilzabrutinib AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper respiratory tract symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline of the mean Forced Vital Capacity in Liters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline of the mean Forced Vital Capacity in %predicted value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Presence of significant NET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Knee injury and Osteoarthritis Outcome Score (KOOS) - Pain subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Patient-reported health-related quality of life (HRQoL) - EQ-5D-5L
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient-reported health-related quality of life (HRQoL) - FOSI
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency of autoimmune T lymphocytes reactive to islet antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: State-Trait Anxiety Inventory (STAI-TX)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: viral load of SARS-CoV-2 virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of metabolic disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vascular reactivity - BOLD amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vascular reactivity - time-to-peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vascular reactivity - time-to-baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Cumulative number of times participants log/view data in the app
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Psychological symptoms assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of interruption of the surgical workflow due to disturbing blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lateral Change of Direction Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 60 Metre Speed Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite outcome of progression of AKI, inpatient dialysis, or inpatient death
Endpoint domain: Mortality/survival
Primary endpoint: Postconcussion symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: appearance of the dew sign
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Force Plate Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-HPV16/18 geometric mean titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Comparison of collection methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Small Intestinal Histology based on Vh:Cd ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient Reported Outcome Surveys (CeD PRO survey evaluation)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Measurement of superoxide anion release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measurement of intracellular ROS formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants with hepatitis B surface antigen (HBsAg) loss at end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean time to successful neutrophil engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean time to successful platelet engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of participants achieving transfusion independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Severe exacerbations of COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Breathlessness cough sputum scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Modified borg RPE scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incentive spirometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Wong-Baker Faces Pain Scale (WBFPS) for Children's Self-Reported Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FLACC (Face, Legs, Activity, Cry, Consolability) Behavioral Pain Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Stimulation-induced motor deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with a new neurological deficit
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in annualized growth velocity (AGV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structural brain connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Application skill evaluation for intramuscular injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: coefficient of variation of the superficial retinal capillary plexus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Erythema assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Re-volumizing performance of the filler ALIAXIN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of urinary incontinence symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes